Clinical Research Directory
Browse clinical research sites, groups, and studies.
DAW2020 on OSA Endotypic Traits
Sponsor: Brigham and Women's Hospital
Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of DAW2020 administered before sleep on OSA phenotype traits and OSA severity during sleep.
Official title: Effect of DAW2020 on Endotypic Traits in OSA
Key Details
Gender
All
Age Range
21 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2020-11-15
Completion Date
2026-12-15
Last Updated
2026-07-15
Healthy Volunteers
No
Conditions
Interventions
Placebo oral capsule
Placebo before sleep
DAW2020 oral capsule
DAW2020 34 mg 4 h before sleep, single night administration
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States